TransMedics' (NASDAQ: TMDX ) stock price has come under pressure in recent weeks due to concerns about a potentially soft third quarter. This largely stems from data on transplant volumes and flight numbers. While TransMedics' growth will continue to decelerate until it opens upRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns ca ...